Hematology Xagena
Final results from the randomized phase 2 GRIFFIN study evaluating the investigational use of Daratumumab ( Darzalex ) in combination with Lenalidomide ( Revlimid ), Bortezomib ( Velcade ) and De ...
R-CHOP chemotherapy remains the standard of care in treatment of fit patients without comorbidities suffering from diffuse large B-cell lymphoma ( DLBCL ), even in elderly patients up to 80 years. A ...
Results from the ongoing pivotal phase 2 clinical trial of Camidanlumab tesirine ( Cami ) in relapsed or refractory ( r/r ) Hodgkin lymphoma were presented at the European Hematology Association 2022 ...
Ponatinib ( Iclusig ) and Blinatumomab ( Blyncito ) are both highly effective therapies for Philadelphia chromosome-positive ( Ph+ ) acute lymphoblastic leukemia ( ALL ). The combination of these tw ...
New data from Cohort 3 of the phase 2 REFINE study of investigational Navitoclax in combination with Ruxolitinib in JAK inhibitor naïve patients with myelofibrosis ( MF ), a rare blood cancer, were an ...
Primary results from the large B-cell lymphoma ( LBCL ) expansion cohort in the EPCORE NHL-1 phase 2 clinical trial evaluating Epcoritamab ( DuoBody-CD3xCD20 ), an investigational subcutaneous bispeci ...
Momelotinib ( MMB ), an oral JAK1/2 and ACVR1/ALK2 inhibitor, has shown clinical activity on myelofibrosis symptoms, red blood cell ( RBC ) transfusion requirements ( anemia ), and spleen volume in th ...
Treatment of polycythemia vera aims to prevent thromboembolic complications, reduce the risk of progression to acute leukemia or myelofibrosis, and ameliorate the symptom burden; specifically, to impr ...
Brexucabtagene autoleucel ( KTE-X19; Brexu-cel; Tecartus ) is an autologous anti-CD19 chimeric antigen receptor ( CAR ) T-cell therapy approved for the treatment of patients with relapsed / refractory ...
Camidanlumab tesirine, an antibody-drug conjugate comprising a human IgG1 anti-CD25 monoclonal antibody conjugated to a pyrrolobenzodiazepine ( PBD ) dimer, displayed antitumor activity and manageable ...
Teclistamab is a BCMA × CD3 T-cell redirecting bispecific antibody under investigation in patients with relapsed / refractory multiple myeloma ( RRMM ). Daratumumab ( Darzalex Faspro) is a CD38 mono ...
Belantamab mafodotin ( Belamaf; Blenrep ), a B-cell maturation antigen ( BCMA ) targeted antibody-drug conjugate approved for adult patients with relapsed / refractory multiple myeloma, has a multimod ...
The results from the ZUMA-12 trial led by researchers at The University of Texas MD Anderson Cancer Center have shown that first-line treatment with Axicabtagene ciloleucel ( Axi-cel; Yescarta ), a ch ...
On the basis of the DREAMM-2 study, single-agent Belantamab mafodotin ( Belamaf; Blenrep ) was approved for patients with relapsed or refractory multiple myeloma ( RRMM ) who received 4 or more prior ...
In patients with transplant-ineligible newly diagnosed multiple myeloma ( NDMM ), Daratumumab ( Darzalex ) has reduced the risk of disease progression or death by 44% in MAIA ( Daratumumab / Lenalidom ...
